June 30, 2016
Nexstim Plc Receives CE Mark Registration for NBT® for Treatment of Chronic Neuropathic Pain
Media
June 28, 2016
Nexstim Plc Key Technology Patent Granted in US
June 28, 2016
Nexstim Plc submits FDA 510(k) De Novo documentation for NBT®
June 28, 2016
Nordic Nanovector and AREVA Med to investigate potential of lead-212 conjugated anti-CD37 antibody for treating leukaemias
June 22, 2016
Targovax ASA: Announcement of successful NOK 110 million private placement
June 14, 2016
Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London
June 14, 2016
Targovax granted US Patent for oncolytic virus ONCOS-102
June 10, 2016
Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity
June 09, 2016
Strongbridge Biopharma plc Announces Executive Promotion and Leadership Transition Fredric Cohen, M.D., Promoted to Senior Vice President, Global Research & Development
June 09, 2016
Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102
